Single and multiple dose pharmacokinetics of felbamate in the elderly

British Journal of Clinical Pharmacology

Volumn 44, Issue 2, 1997, Pages 129-134

  Richens, A ^a   Banfield, C R ^b   Salfi, M ^b   Nomeir, A ^b   Lin, C C ^b   Jensen, P ^b   Affrime, M B ^b   Glue, P ^b  

^a Cardiff Clinical Trials   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Age; Anti epileptic drug; Felbamate; Pharmacokinetics

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE;

ADULT; AGE; AGED; APATHY; AREA UNDER THE CURVE; ARTICLE; ATAXIA; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LABORATORY TEST; MALE; NAUSEA; NORMAL HUMAN; PHARYNGITIS; PRIORITY JOURNAL; SOMNOLENCE; VERTIGO; VOLUNTEER; VOMITING; XEROSTOMIA;

EID: 0030814672     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00642.x     Document Type: Article

References (17)

1. Jensen PK. Felbamate in the treatment of refractory partial onset seizures. Epilepsia 1993; 34(suppl. 7): S25-S29.
2. Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut Syndrome). N Engl J Med 1993; 328: 29-33.
3. 14C-felbamate in healthy men. Epilepsia 1990; 31(suppl. 5): 642.
4. Palmer KJ, McTavish D. Felbamate. Drugs 1993; 45: 1041-1065.
5. Hauser WA, Kurlant LT. The epidemiology of epilepsy in Rochester Minnesota, 1935 through 1975. Epilepsia 1975; 16: 1-66.
6. Hempenius J, Hendriks G, Hingstman J, Mensink CK, Jonkman JHG, Lin CC. An automated analytical method for the determination of felbamate in human plasma by robotic sample preparation and reversed-phase high performance liquid chromatography. J Pharm Biomed Anal 1994; 12: 1443-1451.
7. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed., NewYork, Marcel & Dekker Inc., 1982.
8. Scharf S, Christophidis N. Prescribing for the elderly: relevance of pharmacokinetics and pharmacodynamics. Med J Aust 1993; 158: 395-402.
9. Greenblatt DJ, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol 1989; 29: 866-872.
10. Leppik IE. Metabolism of antiepileptic medication: newborn to elderly. Epilepsia 1992, 33(suppl. 4), S32-S40.
11. Boyd RA, Bockbrader HN, Turck D, Sedman AJ, Posvar EL, Chang T. Effect of subject age on the single dose pharmacokinetics of orally administered gabapentin. Pharm Res 1990; 7 (suppl): S215.
12. Haegele KD, Huebert ND, Ebel M, Tell GP, Schechter PJ. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharmacol Ther 1988; 44: 558-565.
13. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991; 1: 121-128.
14. Tsujimoto G, Hashimoto K, Hoffman BB. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age. Part 2. Int J Clin Pharm Ther Toxicol 1989; 27: 102-116.
15. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures. Neurology 1993; 43: 988-692.
16. Reidenberg P, Glue P, Banfield C, et al. Pharmacokinetic interaction studies between felbamate and vigabatrin. Br J Clin Pharmacol 1995; 40: 157-160.
17. Sachdeo RC, Narang-Sachdeo SK, Howard JR, et al. Steady-state pharmacokinetics and dose proportionality of felbamate after oral administration of 1200, 2400 and 3600 mg/day of felbamate. Epilepsia 1993; 34: 80.